Multi-targeted therapy of cancer by niclosamide: A new application for an old drug

Cancer Letters

Volumn 349, Issue 1, 2014, Pages 8-14

  Li, Yonghe ^a   Li, Pui Kai ^b   Roberts, Michael J ^a   Arend, Rebecca C ^c   Samant, Rajeev S ^d   Buchsbaum, Donald J ^e  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c University of Alabama   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e The University of Alabama at Birmingham   (United States)

Author keywords

Cancer stem cells; Drug discovery; FDA approved drug; Multi targeted therapy; Niclosamide

Indexed keywords

BETA CATENIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; NICLOSAMIDE; NOTCH RECEPTOR; STAT3 PROTEIN; WNT PROTEIN; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CANCER STEM CELL; CANCER THERAPY; DRUG EFFICACY; DRUG TARGETING; GENE TARGETING; HUMAN; IC 50; MITOCHONDRION; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; ANIMAL; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOPLASTIC STEM CELLS; NICLOSAMIDE; SIGNAL TRANSDUCTION;

EID: 84901011400     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.04.003     Document Type: Review

References (77)

1. Andrews P., Thyssen J., Lorke D. The biology and toxicology of molluscicides. Bayluscide Pharmacol. Ther. 1982, 19:245-295.
2. Al-Hadiya B.M. Niclosamide: comprehensive profile. Profiles Drug Subst. Excip. Relat. Methodol. 2005, 32:67-96.
3. Kraljevic S., Stambrook P.J., Pavelic K. Accelerating drug discovery. EMBO Rep. 2004, 5:837-842.
4. Chong C.R., Sullivan D.J. New uses for old drugs. Nature 2007, 448:645-646.
5. Clevers H., Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012, 149:1192-1205.
6. Anastas J.N., Moon R.T. WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer 2013, 13:11-26.
7. Polakis P. Drugging Wnt signalling in cancer. EMBO J. 2012, 31:2737-2746.
8. Chen M., Wang J., Lu J., Bond M.C., Ren X.R., Lyerly H.K., Barak L.S., Chen W. The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. Biochemistry 2009, 48:10267-10274.
9. Osada T., Chen M., Yang X.Y., Spasojevic I., Vandeusen J.B., Hsu D., Clary B.M., Clay T.M., Chen W., Morse M.A., Lyerly H.K. Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res. 2011, 71:4172-4182.
10. Lu W., Lin C., Roberts M.J., Waud W.R., Piazza G.A., Li Y. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/beta-catenin pathway. PLoS ONE 2011, 6:e29290.
11. Londoño-Joshi A., Arend A.C., Aristizabal L., Lu W., Samant R.S., Metge B.J., Hidalgo B., Grizzle W.E., Conner M., Forero-Torres A., LoBuglio A.F., Li Y., Buchsbaum D.J. Effect of niclosamide on basal-like breast cancers. Mol. Cancer Ther. 2014, 13:800-811.
12. Wieland A., Trageser D., Gogolok S., Reinartz R., Hofer H., Keller M., Leinhaas A., Schelle R., Normann S., Klaas L., Waha A., Koch P., Fimmers R., Pietsch T., Yachnis A.T., Pincus D.W., Steindler D.A., Brustle O., Simon M., Glas M., Scheffler B. Anticancer effects of niclosamide in human glioblastoma. Clin. Cancer Res. 2013, 19:4124-4136.
13. Bienz M., Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000, 103:311-320.
14. Stein U., Arlt F., Walther W., Smith J., Waldman T., Harris E.D., Mertins S.D., Heizmann C.W., Allard D., Birchmeier W., Schlag P.M., Shoemaker R.H. The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. Gastroenterology 2006, 131:1486-1500.
15. Sack U., Walther W., Scudiero D., Selby M., Kobelt D., Lemm M., Fichtner I., Schlag P.M., Shoemaker R.H., Stein U. Novel effect of antihelminthic niclosamide on S100A4-mediated metastatic progression in colon cancer. J. Natl. Cancer Inst. 2011, 103:1018-1036.
16. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
17. Dancey J. MTOR signaling and drug development in cancer. Nat. Rev. Clin. Oncol. 2010, 7:209-219.
18. Balgi A.D., Fonseca B.D., Donohue E., Tsang T.C., Lajoie P., Proud C.G., Nabi I.R., Roberge M. Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS ONE 2009, 4:e7124.
19. Fonseca B.D., Diering G.H., Bidinosti M.A., Dalal K., Alain T., Balgi A.D., Forestieri R., Nodwell M., Rajadurai C.V., Gunaratnam C., Tee A.R., Duong F., Andersen R.J., Orlowski J., Numata M., Sonenberg N., Roberge M. Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling. J. Biol. Chem. 2012, 287:17530-17545.
20. Jewell J.L., Russell R.C., Guan K.L. Amino acid signalling upstream of mTOR. Nat. Rev. Mol. Cell Biol. 2013, 14:133-139.
21. Li M., Khambu B., Zhang H., Kang J.H., Chen X., Chen D., Vollmer L., Liu P.Q., Vogt A., Yin X.M. Suppression of lysosome function induces autophagy via a feedback downregulation of MTORC1 activity. J. Biol. Chem. 2013, 288:35769-35780.
22. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.
23. Shuai K., Horvath C.M., Huang L.H., Qureshi S.A., Cowburn D., Darnell J.E. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 1994, 76:821-828.
24. Sasse J., Hemmann U., Schwartz C., Schniertshauer U., Heesel B., Landgraf C., Schneider-Mergener J., Heinrich P.C., Horn F. Mutational analysis of acute-phase response factor/Stat3 activation and dimerization. Mol. Cell. Biol. 1997, 17:4677-4686.
25. Zhong Z., Wen Z., Darnell J.E. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994, 264:95-98.
26. Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415-1421.
27. Boudny V., Kovarik J. JAK/STAT signaling pathways and cancer. Janus kinases/signal transducers and activators of transcription. Neoplasma 2002, 49:349-355.
28. Steelman L.S., Abrams S.L., Whelan J., Bertrand F.E., Ludwig D.E., Basecke J., Libra M., Stivala F., Milella M., Tafuri A., Lunghi P., Bonati A., Martelli A.M., McCubrey J.A. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008, 22:686-707.
29. Ren R., Duan L., He Q., Zhang Z., Zhou Y., Wu D., Pan J., Pei D., Ding K. Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway. ACS Med. Chem. Lett. 2010, 1:454-459.
30. Khanim F.L., Merrick B.A., Giles H.V., Jankute M., Jackson J.B., Giles L.J., Birtwistle J., Bunce C.M., Drayson M.T. Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production. Blood Cancer J. 2011, 1:e39.
31. Li R., Hu Z., Sun S.Y., Chen Z.G., Owonikoko T.K., Sica G.L., Ramalingam S.S., Curran W.J., Khuri F.R., Deng X. Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer. Mol. Cancer Ther. 2013, 12:2200-2212.
32. Li R., You S., Hu Z., Chen Z.G., Sica G.L., Khuri F.R., Curran W.J., Shin D.M., Deng X. Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer. PLoS ONE 2013, 8:e74670.
33. You S., Li R., Park D., Xie M., Sica G.L., Cao Y., Xiao Z.Q., Deng X. Disruption of STAT3 by niclosamide reverses radioresistance of human lung cancer. Mol. Cancer Ther. 2014, 13:606-616.
34. Naugler W.E., Karin M. NF-kappaB and cancer-identifying targets and mechanisms. Curr. Opin. Genet. Dev. 2008, 18:19-26.
35. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
36. Chen F., Castranova V., Shi X., Demers L.M. New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin. Chem. 1999, 45:7-17.
37. Napetschnig J., Wu H. Molecular basis of NF-kappaB signaling. Annu. Rev. Biophys. 2013, 42:443-468.
38. Jin Y., Lu Z., Ding K., Li J., Du X., Chen C., Sun X., Wu Y., Zhou J., Pan J. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer Res. 2010, 70:2516-2527.
39. Sakurai H., Miyoshi H., Toriumi W., Sugita T. Functional interactions of transforming growth factor beta-activated kinase 1 with IkappaB kinases to stimulate NF-kappaB activation. J. Biol. Chem. 1999, 274:10641-10648.
40. Wang C., Deng L., Hong M., Akkaraju G.R., Inoue J., Chen Z.J. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 2001, 412:346-351.
41. Shih Ie M., Wang T.L. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res. 2007, 67:1879-1882.
42. Rizzo P., Osipo C., Foreman K., Golde T., Osborne B., Miele L. Rational targeting of Notch signaling in cancer. Oncogene 2008, 27:5124-5131.
43. Pannuti A., Foreman K., Rizzo P., Osipo C., Golde T., Osborne B., Miele L. Targeting Notch to target cancer stem cells. Clin. Cancer Res. 2010, 16:3141-3152.
44. Wang A.M., Ku H.H., Liang Y.C., Chen Y.C., Hwu Y.M., Yeh T.S. The autonomous notch signal pathway is activated by baicalin and baicalein but is suppressed by niclosamide in K562 cells. J. Cell. Biochem. 2009, 106:682-692.
45. Galluzzi L., Larochette N., Zamzami N., Kroemer G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 2006, 25:4812-4830.
46. Park S.J., Shin J.H., Kang H., Hwang J.J., Cho D.H. Niclosamide induces mitochondria fragmentation and promotes both apoptotic and autophagic cell death. BMB Rep. 2011, 44:517-522.
47. Yo Y.T., Lin Y.W., Wang Y.C., Balch C., Huang R.L., Chan M.W., Sytwu H.K., Chen C.K., Chang C.C., Nephew K.P., Huang T., Yu M.H., Lai H.C. Growth inhibition of ovarian tumor-initiating cells by niclosamide. Mol. Cancer Ther. 2012, 11:1703-1712.
48. Kim S.Y., Kang J.W., Song X., Kim B.K., Yoo Y.D., Kwon Y.T., Lee Y.J. Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell. Signal. 2013, 25:961-969.
49. Wang Y.C., Chao T.K., Chang C.C., Yo Y.T., Yu M.H., Lai H.C. Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells. PLoS ONE 2013, 8:e74538.
50. Pan J.X., Ding K., Wang C.Y. Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells. Chin. J. Cancer 2012, 31:178-184.
51. Shoemaker R.H. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 2006, 6:813-823.
52. Ichikawa K., Liu W., Zhao L., Wang Z., Liu D., Ohtsuka T., Zhang H., Mountz J.D., Koopman W.J., Kimberly R.P., Zhou T. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nature Med. 2001, 7:954-960.
53. Buchsbaum D.J., Zhou T., Grizzle W.E., Oliver P.G., Hammond C.J., Zhang S., Carpenter M., LoBuglio A.F. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin. Cancer Res. 2003, 9:3731-3741.
54. Gongoll S., Peters G., Mengel M., Piso P., Klempnauer J., Kreipe H., von Wasielewski R. Prognostic significance of calcium-binding protein S100A4 in colorectal cancer. Gastroenterology 2002, 123:1478-1484.
55. Sack U., Walther W., Scudiero D., Selby M., Aumann J., Lemos C., Fichtner I., Schlag P.M., Shoemaker R.H., Stein U. S100A4-induced cell motility and metastasis is restricted by the Wnt/beta-catenin pathway inhibitor calcimycin in colon cancer cells. Mol. Biol. Cell 2011, 22:3344-3354.
56. Takenaga K., Nakanishi H., Wada K., Suzuki M., Matsuzaki O., Matsuura A., Endo H. Increased expression of S100A4, a metastasis-associated gene, in human colorectal adenocarcinomas. Clin. Cancer Res. 1997, 3:2309-2316.
57. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
58. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8:755-768.
59. Baccelli I., Trumpp A. The evolving concept of cancer and metastasis stem cells. J. Cell Biol. 2012, 198:281-293.
60. Katoh M., Katoh M. WNT signaling pathway and stem cell signaling network. Clin. Cancer Res. 2007, 13:4042-4045.
61. Merchant A.A., Matsui W. Targeting hedgehog-a cancer stem cell pathway. Clin. Cancer Res. 2010, 16:3130-3140.
62. Takebe N., Harris P.J., Warren R.Q., Ivy S.P. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat. Rev. Clin. Oncol. 2011, 8:97-106.
63. Alison M.R., Lin W.R., Lim S.M., Nicholson L.J. Cancer stem cells: in the line of fire. Cancer Treat. Rev. 2012, 38:589-598.
64. Patrawala L., Calhoun T., Schneider-Broussard R., Zhou J., Claypool K., Tang D.G. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res. 2005, 65:6207-6219.
65. Engelmann K., Shen H., Finn O.J. MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Res. 2008, 68:2419-2426.
66. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C.G., Liu S., Schott A., Hayes D., Birnbaum D., Wicha M.S., Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
67. Croker A.K., Goodale D., Chu J., Postenka C., Hedley B.D., Hess D.A., Allan A.L. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J. Cell. Mol. Med. 2009, 13:2236-2252.
68. Miyazaki Y., Shibuya M., Sugawara H., Kawaguchi O., Hirsoe C. Salinomycin, a new polyether antibiotic. J. Antibiot. 1974, 27:814-821.
69. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., Lander E.S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
70. Huczynski A. Salinomycin: a new cancer drug candidate. Chem. Biol. Drug Des. 2012, 79:235-238.
71. Naujokat C., Steinhart R. Salinomycin as a drug for targeting human cancer stem cells. J. Biomed. Biotechnol. 2012, 2012:950658.
72. Zhou S., Wang F., Wong E.T., Fonkem E., Hsieh T.C., Wu J.M., Wu E. Salinomycin: a novel anti-cancer agent with known anti-coccidial activities. Curr. Med. Chem. 2013, 20:4095-4101.
73. Ketola K., Hilvo M., Hyotylainen T., Vuoristo A., Ruskeepaa A.L., Oresic M., Kallioniemi O., Iljin K. Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. Br. J. Cancer 2012, 106:99-106.
74. Chang Y.W., Yeh T.K., Lin K.T., Chen W.C., Yao H.T., Lan S.J., Wu Y.S., Hsieh H.P., Chen C.M., Chen C.T. Pharmacokinetics of anti-SARS-CoV agent niclosamide and its analogs in rats. J. Food Drug Anal. 2006, 14:329-333.
75. Ziegler S., Pries V., Hedberg C., Waldmann H. Target identification for small bioactive molecules: finding the needle in the haystack. Angew. Chem. Int. Ed. Engl. 2013, 52:2744-2792.
76. Chen H., Yang Z., Ding C., Chu L., Zhang Y., Terry K., Liu H., Shen Q., Zhou J. Discovery of -alkylamino tethered niclosamide derivatives as potent and orally bioavailable anticancer agents. ACS Med. Chem. Lett. 2013, 4:180-185.
77. Mook R.A., Chen M., Lu J., Barak L.S., Lyerly H.K., Chen W. Small molecule modulators of Wnt/beta-catenin signaling. Bioorg. Med. Chem. Lett. 2013, 23:2187-2191.